



Tufts Center for the Study of Drug Development

TUFTS UNIVERSITY

# Impact REPORT

ANALYSIS AND INSIGHT INTO CRITICAL DRUG DEVELOPMENT ISSUES

## 89% of trials meet enrollment, but timelines slip, half of sites under-enroll

*Tufts CSDD study creates benchmark to help plan and manage trials*

- The highest site activation rates are in Western Europe (93%), Eastern Europe (92%), and Asia/Pacific (91%).
- Enrollment achievement rates vary by region, ranging from 75% to 98% of targeted levels, with Asia/Pacific and Latin America having the highest achievement rates.
- Study timelines are typically extended to nearly double their original duration to meet desired enrollment levels for all therapeutic areas.
- 11% of sites in a given trial fail to enroll a single patient, 37% under-enroll, 39% meet their enrollment targets, and 13% exceed their targets.
- Nearly one-third (32%) of studies do not receive centralized recruitment support.
- Centralized recruitment and retention programs utilize traditional tactics, such as physician referrals and newspaper, television, and radio ads, and tend to avoid non-traditional approaches.